Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.66 |
| ▸ | FKBP1A | P62942 | 11/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PREP | P48147 | 3/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159104 | 1.00 | KLK7 (0.66) | KLK7FKBP1AMEN1KMT2APREP | |
| SCHEMBL5970730 | 1.00 | KLK7 (0.66) | KLK7FKBP1AMEN1KMT2APREP | |
| SCHEMBL16531226 | 0.96 | FKBP1A (0.70) | KLK7FKBP1AMEN1KMT2APREP | |
| SCHEMBL221644 | 0.96 | FKBP1A (0.70) | KLK7FKBP1AMEN1KMT2APREP | |
| SCHEMBL13257218 | 0.96 | FKBP1A (0.70) | KLK7FKBP1AMEN1KMT2APREP | |
| SCHEMBL9609458 | 0.96 | KLK7 (0.61) | KLK7FKBP1AMEN1KMT2APREP | |
| SCHEMBL9610764 | 0.96 | KLK7 (0.61) | KLK7FKBP1AMEN1KMT2APREP | |
| SCHEMBL7307432 | 0.96 | KLK7 (0.61) | KLK7FKBP1AMEN1KMT2APREP | |
| SCHEMBL6925800 | 0.94 | FKBP1A (0.64) | KLK7FKBP1AMEN1KMT2APREP | |
| SCHEMBL29447560 | 0.93 | FKBP1A (0.58) | KLK7FKBP1AMEN1KMT2APREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117180290-A | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117186134-A | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-111712302-B | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-3340981-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2022111499-A1 | AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 深圳铂立健医药有限公司 | 2022-06-02 | — | — | WO | disclosed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-112584900-A | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2019159120-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2019-08-22 | — | — | WO | disclosed |
| EP-3340981-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20130177851-A1 | PHOTORESIST COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-11 | — | — | US | disclosed |
| EP-2611797-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | Hanmi Science Co., Ltd. (KR) | 2013-07-10 | — | — | EP | disclosed |
| US-8475999-B2 | Compound and photoresist composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8475999-B2 | Compound and photoresist composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO., LTD (KR) | 2013-06-27 | — | — | US | disclosed |
| WO-2012169785-A9 | SYMMETRICALLY STRUCTURED QUINAZOLINE DERIVATIVES | HANMI SCIENCE CO., LTD. (KR) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012169785-A2 | SYMMETRICALLY STRUCTURED QUINAZOLINE DERIVATIVES | HANMI SCIENCE CO., LTD. (KR) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012030160-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI HOLDINGS CO., LTD. (KR) | 2012-03-08 | — | — | WO | disclosed |
| US-20110039209-A1 | COMPOUND AND PHOTORESIST COMPOSITION CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110039209-A1 | COMPOUND AND PHOTORESIST COMPOSITION CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | CASP7, API5, BAX | KLK7 1633/4885FKBP1A 1214/4885MEN1 1614/4885 |
| US-20110039209-A1 | COMPOUND AND PHOTORESIST COMPOSITION CONTAINING THE SAME | RCOR3, RCN1, HRH4 | KLK7 2213/4885FKBP1A 1811/4885MEN1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.